Merrimack Pharmaceuticals, Inc. (MACK) Financial Analysis & Valuation | Quarter Chart
Merrimack Pharmaceuticals, Inc. (MACK)
MACKPrice: $15.14
Fair Value: 🔒
🔒score
Merrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.
Merrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company was incorporate... more
Description
Shares
| Market Cap | $223.97M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Gary L. Crocker |
| IPO Date | 2012-03-29 | CAGR | — |
| Employees | — | Website | www.merrimack.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
MACK chart loading...
Fundamentals
Technicals
| Enterprise Value | $-21.14M | P/E Ratio | -168.28 |
| Forward P/E | — | PEG Ratio | — |
| P/S Ratio | — | P/B Ratio | 11.55 |
| P/CF Ratio | -142.29 | P/FCF Ratio | -147.16 |
| EPS | $-0.09 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | -100% | Gross Margin | — |
| Operating Margin | — | Profit Margin | — |
| ROE | -0.06% | ROA | -0.06% |
| ROCE | -0.12% | Current Ratio | 43.5 |
| Quick Ratio | 43.5 | Cash Ratio | 13.58 |
| Debt/Equity | — | Interest Coverage | — |
| Altman Z Score | 5 | Piotroski Score | 2 |